Patents Examined by Laura L. Stockton
  • Patent number: 11679092
    Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.
    Type: Grant
    Filed: July 1, 2021
    Date of Patent: June 20, 2023
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
  • Patent number: 11680072
    Abstract: The disclosure includes compounds of Formula (A): wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neurodegenerative disease with these compounds.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: June 20, 2023
    Assignee: Newave Pharmaceutical Inc.
    Inventors: Yi Chen, Yan Lou
  • Patent number: 11667651
    Abstract: The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula: where A, B, R1, X1, X2, and W are described herein.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: June 6, 2023
    Assignee: HiberCell, Inc.
    Inventors: Johan Lindström, Lars Boukharta Persson, Jenny Viklund, Edward A. Kesicki, Eugene R. Hickey, Markus K. Dahlgren, Aleksey I. Gerasyuto
  • Patent number: 11667637
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: June 6, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • Patent number: 11649224
    Abstract: Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: May 16, 2023
    Assignee: Cornell University
    Inventors: Joseph P. Vacca, Dansu Li, Sarah Bettigole
  • Patent number: 11639337
    Abstract: The present invention relates compounds of Formula (A), as well as their preparation and uses, and further relates pharmaceutical compositions comprising these compounds and their uses as modulators of dysfunctional glutamate transmission. The present invention also relates to uses of the compounds or pharmaceutical compositions in treating or preventing certain neurological and psychiatric disorders and diseases as well as cancer in humans.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: May 2, 2023
    Assignee: XWPHARMA LTD.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Wei Zhou
  • Patent number: 11629134
    Abstract: Compounds of Formula 1 and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists.
    Type: Grant
    Filed: December 19, 2020
    Date of Patent: April 18, 2023
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger
  • Patent number: 11608332
    Abstract: Provided are an FGFR4 inhibitor with the structure of formula (I) and a preparation method and use thereof. The series of compounds of formula (I) have a very strong inhibitory effect on the FGFR4 kinase activity, and have a very high selectivity; and the same can be widely used to prepare drugs for treating cancers, in particular, liver cancer, stomach cancer, prostate cancer, skin cancer, ovarian cancer, lung cancer, breast cancer or colon cancer, and it is expected that the same can be developed into a new generation of FGFR4 inhibitor drugs.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: March 21, 2023
    Assignees: Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Shanghai Hansoh Biomedical Co., Ltd.
    Inventors: Peng Gao, Guangjun Sun, Songliang Tan, Lei Liu, Rudi Bao
  • Patent number: 11608329
    Abstract: The present invention provides AHR agonists, compositions thereof, and methods of using the same.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: March 21, 2023
    Assignee: IKENA ONCOLOGY, INC.
    Inventors: Alfredo C. Castro, Karen J. McGovern, Michael Burke
  • Patent number: 11603380
    Abstract: The present invention concerns a compound having the following formula (I): as well as its use as a medicament, especially for its use for treating viral infections.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: March 14, 2023
    Inventors: Luigi Agrofoglio, Vincent Roy, Coralie De Schutter, Maxime Bessieres, Franck Gallardo
  • Patent number: 11591354
    Abstract: The embodiments of the present invention provide a series of thiamine compounds having a hydrocarbon group or a substituted hydrocarbon group attached at (I), wherein the compounds have an inhibitory effect on A?40 and/or A?42.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: February 28, 2023
    Inventors: Chunjiu Zhong, Huan Zhang
  • Patent number: 11584755
    Abstract: Compounds are provided having Formula (I): wherein R, R1, Cyc and A have the meanings provided herein. The compounds have utility in the treatment of diseases, either alone or in combination with other agents.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: February 21, 2023
    Inventors: Hilary Plake Beck, Leah Brigit Cleary, Michael Patrick Dillon, Marcos Gonzalez-Lopez, Luis Ruben P. Martinez, James Clifford Sutton, Jr.
  • Patent number: 11578054
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: February 14, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kap-Sun Yeung, Denis R. St. Laurent, David R. Langley, Paul Michael Scola
  • Patent number: 11578052
    Abstract: Provided herein are compounds and compositions useful in increasing PPAR? activity. The compounds and compositions provided herein are useful for the treatment of PPAR? related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).
    Type: Grant
    Filed: January 29, 2021
    Date of Patent: February 14, 2023
    Assignees: Mitobridge, Inc., The Salk Institute for Biological Studies
    Inventors: Michael Downes, Ronald M. Evans, Arthur Kluge, Bharat Lagu, Masanori Miura, Sunil Kumar Panigrahi, Michael Patane, Susanta Samajdar, Ramesh Senaiar, Taisuke Takahashi
  • Patent number: 11572367
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: July 16, 2020
    Date of Patent: February 7, 2023
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
  • Patent number: 11566001
    Abstract: Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: January 31, 2023
    Inventors: Christopher J. Burns, Glen Coburn, Bin Liu, Jiangchao Yao, Christopher Benetatos, Steven A. Boyd, Stephen M. Condon, Thomas Haimowitz
  • Patent number: 11565999
    Abstract: Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: January 31, 2023
    Assignee: Arixa Pharmaceuticals, Inc.
    Inventors: Eric M. Gordon, Matthew A. J. Duncton, John Freund
  • Patent number: 11555040
    Abstract: The invention is directed to compounds of formula (I), and salts thereof. The compounds are inhibitors of kinase activity, in particular PI3-kinase activity.
    Type: Grant
    Filed: April 16, 2018
    Date of Patent: January 17, 2023
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Andrew Baxter, Sophie Marie Bertrand, Matthew Campbell, Kenneth David Down, Curt Dale Haffner, Julie Nicole Hamblin, Zoe Alicia Henley, William Henry Miller, Eric Philippe Andre Talbot, Jonathan Andrew Taylor
  • Patent number: 11555012
    Abstract: The present invention provides compounds useful as inhibitors of ATP citrate lyase (ACLY), compositions thereof, and methods of using the same.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: January 17, 2023
    Assignee: Nimbus Artemis, Inc.
    Inventors: Silvana Marcel Leit de Moradei, Eric Therrien
  • Patent number: 11547695
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: January 10, 2023
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna